Ombow, >> if some bad news were to come out <<
No matter how confident the company acts about the upcoming data, the reality with biotech trials is always high risk.
CYDY has other irons in the fire like HIV, cancer, etc, but the 2.5 bil market cap depends on the Covid data. I would worry more about these trials and leave the daydreaming (BP deal, uplisting) for later. Biotech is a brutal sector, I've seen too many crash/burns to take anything for granted..